The results from the CiPA Phase II multi-site, blinded validation study are now in. The CiPA team conclusively demonstrated the utility of human stem cell-derived cardiomyocytes to detect drug-induced arrhythmia effects. We are proud that the Maestro MEA system played a pivotal role in the study. We would also like to thank all the Maestro MEA users at big pharma for their great data.
Learn more about CiPA Myocyte studies here.